The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review
Cancer Reports · 2024
DOI: 10.1002/cnr2.1920 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Reports, 2024. Verfasst von Hayder M Al-Kuraishy und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq. Hauptthemen laut MEDLINE: Furin, Adenocarcinoma. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Witten-Herdecke Germany.
Abstract (Originalsprache)
Background
Endometrial adenocarcinoma (EAC) is a malignant tumor of the endometrium. EAC is the most common female malignancy following the menopause period. About 40% of patients with EAC are linked with obesity and interrelated with hypertension, diabetes mellitus, and high circulating estrogen levels. Proprotein convertase (PC) furin was involved in the progression of EAC. Recent findings Furin is a protease enzyme belonging to the subtilisin PC family called PC subtilisin/kexin type 3 that converts precursor proteins to biologically active forms and products. Aberrant activation of furin promotes abnormal cell proliferation and the development of cancer. Furin promotes angiogenesis, malignant cell proliferation, and tissue invasion by malignant cells through its pro‐metastatic and oncogenic activities. Furin activity is correlated with the malignant proliferation of EAC. Higher expression of furin may increase the development of EAC through overexpression of pro‐renin receptors and disintegrin and metalloprotease 17 (ADAM17). As well, inflammatory signaling in EAC promotes the expression of furin with further propagation of malignant transformation.
Conclusion
Furin is associated with the development and progression of EAC through the induction of proliferation, invasion, and metastasis of malignant cells of EAC. Furin induces ontogenesis in EAC through activation expression of ADAM17, pro‐renin receptor, CD109, and TGF‐β. As well, EAC‐mediated inflammation promotes the expression of furin with further propagation of neoplastic growth and invasion.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology and Medicine, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
- Department of Gynecology and Obstetrics, College of Medicine, Mustansiriyah University, Baghdad, Iraq.
- University Centre for Research & Development, Chandigarh University, Chandigarh-Ludhiana Highway, Mohali, Punjab, India.
- Department of Research & Development, Funogen, Athens, Greece.
- Department of Research & Development, AFNP Med, Wien, Austria.
- Department of Science and Engineering, Novel Global Community Educational Foundation, Hebersham, New South Wales, Australia.
ORCID-Profile: Athanasios Alexiou, Hebatallah M Saad
Förderung
- University of Witten-Herdecke Germany
Zitieren
APA
Al-Kuraishy, H. M., Al-Maiahy, T. J., Al-Gareeb, A. I., Alexiou, A., Papadakis, M., Saad, H. M., & Batiha, G. E. (2024). The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review. Cancer Reports. https://doi.org/10.1002/cnr2.1920
Vancouver
Al-Kuraishy HM, Al-Maiahy TJ, Al-Gareeb AI, Alexiou A, Papadakis M, Saad HM, et al. The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review. Cancer Reports. 2024. doi:10.1002/cnr2.1920
BibTeX
@article{AlKuraishy2024,
author = {Al-Kuraishy, Hayder M and Al-Maiahy, Thabat J and Al-Gareeb, Ali I and Alexiou, Athanasios and Papadakis, Marios and Saad, Hebatallah M and Batiha, Gaber El-Saber},
title = {The possible role furin and furin inhibitors in endometrial adenocarcinoma: A narrative review},
journal = {Cancer Reports},
year = {2024},
doi = {10.1002/cnr2.1920}
}
EUVIMED